{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:55:15Z","timestamp":1794412515931,"version":"4.9.0"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Metastatic colorectal cancer (mCRC) is a common and high-risk malignant tumor. Fruquintinib is a novel small-molecule compound with high selective inhibition of vascular endothelial growth factor (VEGF) receptor (VEGFR) for mCRC for which second-line or higher standard chemotherapy has been ineffective. A female patient with mCRC developed severe rashes after 2 weeks of taking fruquintinib. Considering the relationship between fruquintinib and the rashes, she discontinued taking the drug, and her condition improved. Although fruquintinib has shown good safety and manageable toxicity in previous trials, the patient in the present case developed severe rashes after 2 weeks of taking fruquintinib. The common skin reactions of hand and foot are erythema and paresthesia of hand and foot. Because few people have reported a severe rash caused by fruquintinib, which is different from the common hand foot skin reaction. We hope the case attracts the attention of oncologists.<\/jats:p>","DOI":"10.3389\/fonc.2021.688231","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:43:23Z","timestamp":1625492603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Yefei","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30345-0","article-title":"The Global, Regional, and National Burden of Colorectal Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S215533","article-title":"Fruquintinib: A Novel Antivascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor for the Treatment of Metastatic Colorectal Cancer","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1630272","article-title":"The Clinical Application of Fruquintinib on Colorectal Cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0454","article-title":"Fruquintinib and its Use in the Treatment of Metastatic Colorectal Cancer","volume":"15","author":"Deng","year":"2019","journal-title":"Future Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0998-z","article-title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial","volume":"78","author":"Li","year":"2018","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0998-z","article-title":"Fruquintinib: First Global Approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.918411","article-title":"Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients With Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials","volume":"25","author":"Chen","year":"2019","journal-title":"Med Sci Monit"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.688231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:43:26Z","timestamp":1625492606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.688231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":8,"alternative-id":["10.3389\/fonc.2021.688231"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.688231","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"688231"}}